1372P Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK+) advanced solid tumors, including NSCLC: Update from the phase I/II TRIDENT-1 trial

著者: Benjamin Solomon, Alexander Drilon, W. Marston Linehan, Lyudmila Bazhenova, Keiko Goto, J. De Langen, Dongwook Kim, Jennifer Moriatis Wolf, Christoph Springfeld, Sanjay Popat, Wan‐Teck Lim, Christina S. Baik, Alice Hervieu, V. Moreno Garcia, Nong Yang, S. Thamake, Felipe Ades, D. Trone, Benjamin Besse - Annals of Oncology 2023 被引用: 56